Neogen is OVERVALUED at 12.58 per share with modest projections ahead. Over 94.0% of Neogen shares are owned by
institutional investors. Institutional ownership of Neogen refers to the amount of Neogen equity owned by mutual funds, pension funds, insurance companies, investment firms, foundations, or other large entities that manage money on behalf of others. Check out our latest analysis of Neogen, including its current
ownership diagnostics.
There are currently many different techniques concerning forecasting the market as a whole as well as
predicting future values of individual securities such as Neogen. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the
market sentiment and impact your forecasting results.
Predictive Modules for Neogen
How important is Neogen's Liquidity
Neogen
financial leverage refers to using borrowed capital as a funding source to finance Neogen ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Neogen financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Neogen's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Neogen's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Neogen's total debt and its cash.
Neogen Gross Profit
Neogen Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Neogen previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Neogen Gross Profit growth over the last 10 years. Please check Neogen's
gross profit and other
fundamental indicators for more details.
A Deeper look at Neogen
Neogen currently demonstrates below-average downside deviation. It has Information Ratio of -0.02 and Jensen Alpha of -0.21. However, we advise investors to further question Neogen expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Neogen's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Neogen's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Another 3 percent surge for Neogen
Latest skewness is at 0.69.
As of the 4th of January, Neogen secures the Risk Adjusted Performance of 0.0541,
mean deviation of 2.5, and Downside Deviation of 2.96. In connection with
fundamental indicators, the
technical analysis model lets you check existing technical drivers of Neogen, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to break down and interpolate data for nineteen
technical drivers for Neogen, which can be compared to its peers in the industry. Please verify
Neogen treynor ratio, as well as the
relationship between the downside variance and
kurtosis to decide if Neogen is priced some-what accurately, providing market reflects its recent price of 15.68 per share. Given that Neogen has
jensen alpha of
(0.21), we recommend you to check Neogen's last-minute market performance to make sure the company can sustain itself at a future point.
Our Bottom Line On Neogen
Although some other companies within the diagnostics & research industry are still a little expensive, even after the recent corrections, Neogen may offer a potential longer-term growth to shareholders. To conclude, as of the 4th of January 2023, we believe that at this point, Neogen is
overvalued with
below average odds of financial distress within the next 2 years. Our present buy-or-sell advice on the firm is
Strong Sell.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Neogen. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
